Biotech Values

[NP1986]

And, specific to PPHM, it's important to note that bavi was worse than a comparator that may not even be around long-term given the push for all-oral HCV DAA regimens. Very hard to take this drug seriously.

Exactly, and the notion that PPHM will find a partner willing to fund a phase III trial (as claimed by some PPHM longs) is patently silly.